Clinical Medicine Reviews in Therapeutics 2010:2
Review
Published on 23 Mar 2010
DOI: 10.4137/CMRT.S1618
Sign up for email alerts to receive notifications of new articles published in Clinical Medicine Reviews in Therapeutics
Goals of treatment for ulcerative colitis (UC) include inducing remission, reducing symptom burden, and maintaining disease quiescence. Mesalamine is indicated for the management of mild to moderate ulcerative colitis. There are various dosages, formulations, and mechanisms of delivery that are efficacious and currently utilized in the treatment of UC. Mesalamine therapy (formulation and dosage) should be tailored on an individual basis depending on extent and severity of disease. Newer delivery systems can consolidate dosing regimens and possibly increase compliance. In general, mesalamine has been well tolerated with minimal side effects. In addition, mesalamine has been postulated to play a role in the chemoprophylaxis of colon cancer in patients with ulcerative colitis.
RIS citation (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)
BibTex citation (BIBDESK, LATEX)
Facebook Twitter
Pinterest